Tagged with R

Quintiles Netherlands As an expatriate executive, you seem to be fully integrated into the local community. Can you explain to our readers what brought you here to the Netherlands? The quick answer is the charm of the Dutch. Perhaps more importantly, what’s kept me here has been the opportunity to be involved…

Beurs van Berlage The Beurs van Berlage, conference centre in the heart of Amsterdam, dates back to the year 1903, and is a significant Dutch monument and unique event center that has become a famous heritage of the country. In what ways does Beurs van Berlage reflect and serve the city of Amsterdam…

Atlantic Healthcare Ltd A key milestone for Atlantic Healthcare was the deal with Isis Pharmaceuticals for alicaforsen in 2007. In 2008, alicaforsen acquired orphan drug status in the U.S.; in 2009, orphan status was granted in Europe. Many companies in the UK have named market access as a key challenge—but is that an…

Merck Sp. z.o.o You joined Merck in September 1996, took gradually increasing positions at Merck, from Medical Representative (1996 – 1998), to Sales and Marketing managing positions and you were ultimately appointed Managing Director Poland in January 2008. What have been the major challenges you faced in almost three years now? Merck in…

Pfizer Polska You have been appointed at the head of Pfizer Poland last December. 2010 is a hot year for the group – even very hot for some of the top management – What has been the most challenging thing for you to deal with in this first year in Poland? The…

Novo Nordisk Pharma Sp. z.o.o Apart from Poland being a 40 million population market, with double digit growth, Mr. Kuczynski of Pierre Fabre was telling us that the main opportunity of the Polish market lies in the many unmet, local medical needs. What are the main specificities of the Polish market in your view and…

PharmaExpert What is PharmaExpert’s role in the Polish pharmaceutical industry? The information that PharmaExpert gathers enables us to give good insight about the evolution of the pharmacists market, the evolution of the prices in the pharma landscape, and of the level of reimbursement, among others. PharmaExpert created a model of explanation…

Bayer Co. Malaysia / Bayer Healthcare Malaysi Can you give our readers an outline of Bayer’s background in Malaysia and its current organisational division? Herbert Dittmar (HD): Bayer has been in Malaysia for around fifty years. It established its first legal entity here in the early 1970s and then engaged in a number of acquisitions worldwide including…

Malaysian Biotech Organisation (MBIO) Kebangsaan Malaysia (UKM). Singapore and Taiwan are known for their high level of basic research and their focus on Biotechnology. Philip Yeo, Chairman of Spring Singapore told us that Biomedical science was an undisputed pillar of Singapore’s economy. How do you situate Malaysia in terms of R&D compared to other…

Cegedim Strategic Data Malaysia Nowadays we can talk of an abundance of information coming from companies like Frost& Sullivan, IMS and even consultancies who are producing their own data. As a leader in market research how can CSD find a space within this picture and what strategies does it employ to stay ahead of…

Top Institute Pharma There is a very interesting history behind the origins of Top Institute Pharma (TI Pharma) as it aligned the interests of both the World Health Organization (Priority Medicines) and the EU’s Lisbon Strategy. Lisbon’s goal in 2000 was to transform the EU into the most powerful knowledge economy by 2010…

Vifor Pharma UK Ltd You joined Vifor Pharma to establish a new structure in the UK. It is quite difficult to set up a new enterprise—what have been the main challenges for yourself and the organization in the year since Vifor Pharma UK came into being? I was actually the first employee of Vifor…